[The effect of myosin ATPase inhibition on metabolic and functional recovery of isolated rat heart after global ischemia].
The effect of myosin ATPase inhibitor, 2,3-butanedione monoxime (BDM; used in the range of concentrations 1.25-10.0 mM), on recovery of functions of isolated rat heart subjected to normothermic (37 degrees C) total ischemia for 35 min has been investigated. BDM perfusion was performed at a flow rate of 4 ml/min during 5 min before ischemia (BDM-I) or before 25-min reperfusion (BDM-R). Control hearts were perfused with Krebs solution at the same flow rate. The highest functional recovery of heart and coronary vessels was observed during infusion of 2.5 mM BDM before ischemia. At the end of reperfusion ATP and phosphocreatine (PCr) content in hearts of this group was significantly higher whereas the level of lactate was two times lower than in control; total creatine content (sigmaCr) did not differ from the initial level. Similar but less pronounced changes in the improvement of aerobic metabolism and maintenance of sigmaCr after reperfusion were also observed in the case of infusion of 2.5 mM BDM before reperfusion. They were consistent with reduced recovery of functions of heart and coronary flow compared with these parameters observed in the BDM-I group. 2.5 mM BDM caused almost 2-fold decrease in release of cardiac lactate dehydrogenase into myocardial perfusate in the BDM-I and BDM-R groups (compared with control); this suggests lower damage of cell membranes. These results suggest that improvement of energy supply of postischemic cardiomyocytes may be a key factor determining cardioprotector effectiveness of short-term administration of BDM before ischemia.
Pisarenko
O I
OI
Shul'zhenko
V S
VS
Studneva
I M
IM
D000818:Animals; D002462:Cell Membrane / Q000187:drug effects / Q000378:metabolism; D003326:Coronary Circulation / Q000187:drug effects; D003931:Diacetyl / Q000031:analogs & derivatives* / Q000494:pharmacology; D006321:Heart / Q000187:drug effects* / Q000503:physiopathology; D066298:In Vitro Techniques; D017202:Myocardial Ischemia / Q000378:metabolism* / Q000503:physiopathology*; D015425:Myocardial Reperfusion; D009206:Myocardium / Q000378:metabolism*; D032383:Myocytes, Cardiac / Q000187:drug effects / Q000378:metabolism; D009218:Myosins / Q000037:antagonists & inhibitors*; D051381:Rats; D017208:Rats, Wistar
C004717:diacetylmonoxime; D009218:Myosins; D003931:Diacetyl